|
06/01/2020
|
Summary ToggleNovus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media
|
|
05/15/2020
|
Summary ToggleNovus Therapeutics Reports First Quarter 2020 Financial Results
|
|
03/17/2020
|
Summary ToggleNovus Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results
|
|
03/02/2020
|
Summary ToggleNovus Therapeutics Completes Enrollment of Phase 2a Trial of OP0201 in Pediatric Patients with Acute Otitis Media
|
|
01/13/2020
|
Summary ToggleNovus Therapeutics Provides Update on OP0201
|
|
01/10/2020
|
Summary ToggleNovus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
|
|
11/29/2019
|
Summary ToggleNovus Therapeutics to Participate in Two Investor Conferences
|
|
11/13/2019
|
Summary ToggleNovus Therapeutics Reports Third Quarter 2019 Financial Results
|
|
10/29/2019
|
Summary ToggleNovus Therapeutics Receives FDA Guidance on OP0201 Phase 2a Study in Patients with Chronic Otitis Media with Effusion
|
|
08/29/2019
|
Summary ToggleNovus Therapeutics to Participate in Two Upcoming Investor Conferences
|
